Apixaban: A Review in Venous Thromboembolism

Overview

Journal Drugs

Specialty Pharmacology

Date 2016 Sep 23

PMID 27653758

Citations 10

Authors

Sarah L Greig

Karly P Garnock-Jones

Affiliations

Soon will be listed here.

Abstract

Apixaban (Eliquis) is an oral, direct factor Xa inhibitor that is available for use in the treatment and secondary prevention of venous thromboembolism (VTE). Like other direct oral anticoagulants (DOACs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring. In large phase III trials, oral apixaban was noninferior to subcutaneous enoxaparin sodium overlapped with and followed by oral warfarin (enoxaparin/warfarin) in the treatment of adults with acute VTE over 6 months with regard to the incidence of recurrent VTE or VTE-related death (AMPLIFY), and was significantly more effective than placebo in the prevention of recurrent VTE or all-cause mortality over 12 months in patients who had completed 6-12 months' anticoagulation treatment for VTE (AMPLIFY-EXT). Apixaban was generally well tolerated in these trials; the risks of major bleeding and the composite endpoint of major or clinically relevant nonmajor (CRNM) bleeding with apixaban were significantly lower than enoxaparin/warfarin in AMPLIFY and not significantly different from that of placebo in AMPLIFY-EXT. Similarly, in Japanese adults with acute VTE (AMPLIFY-J), apixaban was associated with a significantly lower risk of major or CRNM bleeding than unfractionated heparin plus warfarin, and no cases of recurrent VTE or VTE-related death over 24 weeks. Thus, apixaban is useful therapeutic alternative for the management of adults with VTE.

Citing Articles

Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up.

Ain N, Ali N, Ullah A, Ullah S, Ahmad S Medicina (Kaunas). 2024; 60(10).

PMID: 39459499 PMC: 11509751. DOI: 10.3390/medicina60101712.

Quality-by-Design-Driven Nanostructured Lipid Scaffold of Apixaban: Optimization, Characterization, and Pharmacokinetic Evaluation.

Patil K, Gujarathi N, Sharma C, Ojha S, Goyal S, Agrawal Y Pharmaceutics. 2024; 16(7).

PMID: 39065607 PMC: 11280014. DOI: 10.3390/pharmaceutics16070910.

Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents.

Zhang Y, Wu C, Zhang N, Fan R, Ye Y, Xu J Int J Mol Sci. 2023; 24(16).

PMID: 37628906 PMC: 10454718. DOI: 10.3390/ijms241612724.

Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban.

Zaky M, Hammady T, Gad S, Alattar A, Alshaman R, Hegazy A Pharmaceutics. 2023; 15(6).

PMID: 37376116 PMC: 10302406. DOI: 10.3390/pharmaceutics15061668.

Tailoring Apixaban in Nanostructured Lipid Carrier Enhancing Its Oral Bioavailability and Anticoagulant Activity.

Zaky M, Megahed M, Hammady T, Gad S, Ghorab M, El-Say K Pharmaceutics. 2023; 15(1).

PMID: 36678709 PMC: 9867073. DOI: 10.3390/pharmaceutics15010080.

References

Frost C, Nepal S, Byon W, Moore K, Reeves R, Boyd R . Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval. J Clin Pharmacol. 2014; 55(5):549-55. DOI: 10.1002/jcph.447. View

Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N . 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35(43):3033-69, 3069a-3069k. DOI: 10.1093/eurheartj/ehu283. View

Frost C, Wang J, Nepal S, Schuster A, Barrett Y, Mosqueda-Garcia R . Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2012; 75(2):476-87. PMC: 3558798. DOI: 10.1111/j.1365-2125.2012.04369.x. View

Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd R . Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2013; 14(2):147-54. PMC: 3961628. DOI: 10.1007/s40256-013-0055-y. View

Mantha S, Ansell J . Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis. 2014; 39(2):155-65. DOI: 10.1007/s11239-014-1102-5. View

. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011; 75(5):1258-81. DOI: 10.1253/circj.cj-88-0010. View

Nakamura M, Nishikawa M, Komuro I, Kitajima I, Uetsuka Y, Yamagami T . Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study). Circ J. 2015; 79(6):1230-6. DOI: 10.1253/circj.CJ-15-0195. View

Finks S, Trujillo T, Dobesh P . Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother. 2016; 50(6):486-501. PMC: 4871170. DOI: 10.1177/1060028016632785. View

Liu X, Thompson J, Phatak H, Mardekian J, Porcari A, Johnson M . Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial. Thromb Haemost. 2015; 115(1):161-8. DOI: 10.1160/TH15-07-0606. View

10.

Frost C, Byon W, Song Y, Wang J, Schuster A, Boyd R . Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2014; 79(5):838-46. PMC: 4415720. DOI: 10.1111/bcp.12541. View

11.

Boey J, Gallus A . Drug Treatment of Venous Thromboembolism in the Elderly. Drugs Aging. 2016; 33(7):475-90. DOI: 10.1007/s40266-016-0378-x. View

12.

Vakkalagadda B, Frost C, Byon W, Boyd R, Wang J, Zhang D . Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016; 16(2):119-27. DOI: 10.1007/s40256-015-0157-9. View

13.

Agnelli G, Buller H, Cohen A, Gallus A, Lee T, Pak R . Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015; 13(12):2187-91. DOI: 10.1111/jth.13153. View

14.

Lanitis T, Leipold R, Hamilton M, Rublee D, Quon P, Browne C . Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence. Clin Ther. 2016; 38(3):478-93.e1-16. DOI: 10.1016/j.clinthera.2016.01.020. View

15.

Hirschl M, Kundi M . New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons. Vasa. 2014; 43(5):353-64. DOI: 10.1024/0301-1526/a000373. View

16.

Nicolaides A, Fareed J, Kakkar A, Comerota A, Goldhaber S, Hull R . Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol. 2014; 32(2):111-260. View

17.

Deeks E . Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. Drugs. 2012; 72(9):1271-91. DOI: 10.2165/11209020-000000000-00000. View

18.

Buller H, Deitchman D, Prins M, Segers A . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008; 6(8):1313-8. DOI: 10.1111/j.1538-7836.2008.03054.x. View

19.

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

20.

Barrett Y, Wang Z, Frost C, Shenker A . Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010; 104(6):1263-71. DOI: 10.1160/TH10-05-0328. View